Malignant tumor metastasis inhibitors
    2.
    发明授权
    Malignant tumor metastasis inhibitors 失效
    恶性肿瘤转移抑制剂

    公开(公告)号:US06566351B1

    公开(公告)日:2003-05-20

    申请号:US09091185

    申请日:1998-06-10

    IPC分类号: A61K3159

    CPC分类号: A61K31/593 A61K31/59

    摘要: Pharmaceutical agents containing a compound of the general formula (I): wherein R1 represents —O—R2, —S—R2, —CH2—R2 or —CH═R2 where R2 represents a C1-C10 chain hydrocarbon group which may be substituted by one or more hydroxyl groups, and R3 represents a hydrogen atom or a hydroxyl group are useful as malignant tumor metastasis inhibitors without any especially strong side effects.

    摘要翻译: 含有通式(I)化合物的药剂:其中R1表示-O-R2,-S-R2,-CH2-R2或-CH = R2,其中R2表示C1-C10链烃基,其可以被 一个或多个羟基,R 3表示氢原子或羟基,可用作恶性肿瘤转移抑制剂而没有任何特别强的副作用。

    Monitoring method of renal lesions without clinical signs
    3.
    发明授权
    Monitoring method of renal lesions without clinical signs 失效
    肾脏病变监测方法无临床症状

    公开(公告)号:US5662604A

    公开(公告)日:1997-09-02

    申请号:US495635

    申请日:1995-09-19

    IPC分类号: C12Q1/34 A61K38/00

    CPC分类号: C12Q1/34 G01N2333/924

    摘要: A screening method for detecting renal lesions in diabetic patients not yet exhibiting symptoms of nephropathy, comprising administering a predetermined dose of parathyroid hormone, analogue thereof or derivative thereof to the patients with an albumin excretion rate (AER) of microalbumin being below 15 .mu.g/min., measuring urinary excreted N-acetyl-.beta.-D-glucosaminidase (NAG) and urinary creatinine in urinary samples taken 60.+-.10 minutes before and after administration of PTH, and monitoring the increased ratio of urinary excreted NAG (U/g Cr) in post-administration of PTH to the urinary excreted NAG (U/g Cr) in pre-administration of PTH for a value less than 2.3. The screening method provides the possibility of detecting renal lesions without clinical signs of diabetic nephropathy, using a preparation essentially consisting of active ingredient of PTH.

    摘要翻译: PCT No.PCT / JP93 / 00178 Sec。 371 1995年9月19日第 102(e)1995年9月19日PCT 1993年2月12日提交PCT未检测出肾病症状的糖尿病患者的肾脏损害检测方法,其特征在于,向患者施用预定量的甲状旁腺激素,其类似物或其衍生物 微量白蛋白的白蛋白排泄率(AER)低于15μg/ min,在尿样中测量尿排泄的N-乙酰基-β-D-氨基葡萄糖苷酶(NAG)和尿肌酐,在前后60±10分钟内摄取 给予PTH,并监测在PTH给药前尿中排泄的NAG(U / g Cr)与PTH前期尿液排泄的NAG(U / g Cr)的比例增加,小于2.3。 筛选方法提供了检测肾病变的可能性,没有糖尿病肾病的临床体征,使用基本上由PTH活性成分组成的制剂。

    Agents for ameliorating low vasopressin level
    4.
    发明授权
    Agents for ameliorating low vasopressin level 失效
    改善低血管加压素水平的药物

    公开(公告)号:US07655227B1

    公开(公告)日:2010-02-02

    申请号:US10019501

    申请日:2000-07-03

    CPC分类号: C07K16/26

    摘要: The present invention provides an agent for ameliorating low vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof; and an agent for ameliorating a symptom caused by a decrease in vasopressin level, which comprises, as an active ingredient, a substance capable of inhibiting the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

    摘要翻译: 本发明提供一种用于改善低加压素水平的药剂,其包含作为活性成分的能够抑制甲状旁腺激素相关肽(PTHrP)与其受体之间的结合的物质; 以及用于改善由加压素水平降低引起的症状的药剂,其包含作为活性成分的能够抑制甲状旁腺激素相关肽(PTHrP)与其受体之间的结合的物质。

    Malignant tumor metastasis inhibitors
    5.
    发明授权
    Malignant tumor metastasis inhibitors 失效
    恶性肿瘤转移抑制剂

    公开(公告)号:US06869940B2

    公开(公告)日:2005-03-22

    申请号:US10135846

    申请日:2002-05-01

    IPC分类号: A61K31/59 A61K31/593

    CPC分类号: A61K31/59 A61K31/593

    摘要: A method for inhibiting bone metastasis of a malignant tumor in a patient who has a cancer excluding breast cancer comprises administering to said patient an effective amount of a compound of the formula (III): wherein R2 represents a C1-C10 alkyl group substituted by one or more hydroxyl groups is provided.

    摘要翻译: 一种抑制患有除了乳腺癌以外的癌症的患者中的恶性肿瘤的骨转移的方法包括向所述患者施用有效量的式(III)化合物:其中R 2表示被一个 或更多的羟基。